Type 2 Diabetes

Adults with type 2 diabetes are more likely to report falls and fear of falling than those without diabetes, regardless of the presence of diabetic polyneuropathy, according to a study published in Diabetic Medicine.

Moderate alcohol consumption is associated with an increased risk for advanced fibrosis in nonalcoholic fatty liver disease, with the risk highest among those with type 2 diabetes, according to study data.

In this exclusive video, Colleen Cutcliffe, PhD, CEO and co-founder of Pendulum Therapeutics, discussed two strains of probiotics that the company is currently looking at. Patients with type 2 diabetes are missing strains to enable metabolizing fiber and albuterate and to regulate the mucin layer. Cutcliffe said Pendulum has developed a probiotic, which in a randomized placebo-controlled trial showed efficacy is patients with type 2 diabetes and dropped glucose by 30%.

Individuals with type 1 diabetes and those with type 2 diabetes have similar increased risks for COVID-19 hospitalization and severe illness compared with those without diabetes, according to a study published in Diabetes Care.

Adults owning a dog with diabetes are more likely to develop type 2 diabetes than an owner of a dog without diabetes, according to a study published in BMJ.

CV outcomes of finerenone (Bayer) vs. placebo in patients with type 2 diabetes and chronic kidney disease.

Increasing age at type 2 diabetes diagnosis is associated with progressively lower risks for all-cause mortality, macrovascular and microvascular disease, according to findings from a systematic review of 26 studies.

The inextricable, well-documented link between the twin epidemics of nonalcoholic fatty liver disease, or NAFLD, and type 2 diabetes has raised alarms in the medical community.

The inextricable, well-documented link between the twin epidemics of nonalcoholic fatty liver disease, or NAFLD, and type 2 diabetes has raised alarms in the medical community.

Poxel announced additional positive phase 2a results and plans for a phase 2b trial of PXL770, an oral direct adenosine monophosphate-activated protein kinase activator intended for nonalcoholic steatohepatitis.